ArticleJHEP reports : innovation in hepatology2026
Spatial profiling defines three immunophenotypes and a perineural invasion-associated immune-evasion niche in gallbladder cancer.
Article in JHEP reports : innovation in hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsGallbladder cancer (GBC) has a high risk of postoperative recurrence, and immunotherapy-based adjuvant approaches remain unstandardised. We aimed to define spatial immunophenotypes in GBC and evaluate their associations with clinical outcomes and immune-evasion mechanisms.
methodsWe used multiplex immunohistochemistry to quantify 16 immune-cell subsets across the tumour core, tumour margin and peritumour regions in 86 treatment-naïve GBCs, and integrated nerve bundle-centred spatial analysis with transcriptomic profiling (n = 9) to investigate perineural invasion (PNI)-associated immune-evasion mechanisms.
resultsUnsupervised clustering and a CD8/α-SMA dual-marker approach defined three spatial immunophenotypes: immune-inflamed, immune-excluded, and immune-desert. The immune-inflamed phenotype featured high intratumoural immune infiltration with elevated PD-L1 expression (median combined positive score: 13.85 vs. 0.41 vs. 0.25, p <0.001), was associated with better prognosis (overall survival [OS]: hazard ratio [HR] 0.25, 95% CI 0.12-0.54, p <0.001; recurrence-free survival [RFS]: HR 0.41, 95% CI 0.21-0.79, p = 0.008), and improved outcomes with adjuvant chemoimmunotherapy vs. chemotherapy alone (OS: HR 0.10, 95% CI 0.02-0.48, p <0.001; RFS: HR 0.29, 95% CI 0.12-0.70, p = 0.003). The immune-excluded phenotype was stroma-enriched (α-SMA, p <0.001), with immune cells largely restricted to the tumour margin or peritumour regions; the immune-desert phenotype showed sparse immune infiltration. PNI was associated with immunosuppressive chronic inflammation, characterised by enrichment of PD-L1
conclusionsWe defined three spatial immunophenotypes in GBC with distinct immune features and clinical outcomes. PNI was associated with the formation of a local immune-evasion niche. IMPACT AND IMPLICATIONS: GBC lacks validated biomarkers to guide postoperative immunotherapy, whereas spatial immune architecture provides a clinically meaningful indicator of tumour immune heterogeneity. By defining three spatial immunophenotypes, we delineate their distinct clinical outcomes and immune-evasion features. Moreover, we demonstrate an association between PNI and the formation of a local immune-evasion niche. These findings may inform clinicians and clinical trialists seeking to optimise postoperative risk stratification and adjuvant treatment strategies, and researchers investigating PNI-related molecular mechanisms. Clinically, integrating spatial immunophenotyping with PNI assessment into routine pathology workflows may improve prognostic stratification and inform adjuvant treatment decisions; however, prospective validation is required before broad clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.